BDX trades 5.3% above Wall Street's consensus target of $200.57.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BDX achieves its forward estimates and maintains a stable P/E multiple of 16.7x. This scenario reflects the blended consensus of 34 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Becton, Dickinson and Company (BDX) has a Wall Street consensus price target of $200.57, based on estimates from 34 covering analysts. With the stock currently trading at $211.88, this represents a potential downside of -5.3%. The company has a market capitalization of $58.38B.
Analyst price targets range from a low of $165.00 to a high of $242.00, representing a 38% spread in expectations. The median target of $190.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 17 analysts rating the stock as a Buy or Strong Buy,16 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BDX trades at a trailing P/E of 36.3x and forward P/E of 16.7x. The forward PEG ratio of 1.01 indicates reasonable valuation for growth. Analysts expect EPS to grow +270.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $244.12, with bear and bull scenarios of $153.79 and $321.65 respectively. Model confidence stands at 51/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 BAXBaxter International Inc. | $13.3B | $25.79 | $23.83 | -7.6% | Hold | 12.3x | 36 |
 BSXBoston Scientific Corporation | $63.5B | $42.75 | $54.65 | +27.8% | Buy | 13.5x | 44 |
 MDTMedtronic plc | $130.7B | $101.80 | $97.73 | -4.0% | Buy | 17.0x | 51 |
 SYKStryker Corporation | $124.9B | $325.78 | $354.47 | +8.8% | Buy | 22.0x | 52 |
 ZBHZimmer Biomet Holdings, Inc. | $20.4B | $105.59 | $109.11 | +3.3% | Hold | 12.4x | 42 |
 EWEdwards Lifesciences Corporation | $58.8B | $102.14 | $108.70 | +6.4% | Buy | 34.0x | 49 |
 ABTAbbott Laboratories | $191.5B | $109.93 | $121.36 | +10.4% | Buy | 19.9x | 43 |
 DHRDanaher Corporation | $161.9B | $230.25 | $238.77 | +3.7% | Buy | 26.8x | 43 |
 TMOThermo Fisher Scientific Inc. | $258.2B | $694.76 | $694.27 | -0.1% | Buy | 27.5x | 43 |
 HSICHenry Schein, Inc. | $9.8B | $86.05 | $97.14 | +12.9% | Buy | 15.7x | 34 |
Quick answers to the most common questions about buying BDX stock.
Wall Street's consensus price target for BDX is $200.57, -5.3% from its current price of $211.88. The below-market target from 34 analysts suggests limited near-term appreciation.
BDX has a consensus rating of "Buy" based on 34 Wall Street analysts. The rating breakdown is mixed, with 16 Hold ratings making up the largest segment. The consensus 12-month price target of $200.57 implies -5.3% downside from current levels.
With a forward P/E of 16.7199x, BDX trades at a relatively low valuation. The consensus target of $200.57 implies -5.3% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $242 for BDX, while the most conservative target is $165. The consensus of $200.57 represents the median expectation. Our quantitative valuation model projects a bull case target of $322 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
BDX is heavily covered by Wall Street, with 34 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 17 have Buy ratings, 16 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BDX stock forecast based on 34 Wall Street analysts shows a consensus price target of $200.57, with estimates ranging from $165 (bear case) to $242 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $244, with bear/bull scenarios of $154/$322.
Our quantitative valuation model calculates BDX's fair value at $244 (base case), with a bear case of $154 and bull case of $322. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.
BDX trades at a forward P/E ratio of 16.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 36.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on BDX, with 1 Sell ratings and a price target of $200.57 (-5.3% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BDX analyst price targets range from $165 to $242, a 38% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $200.57 consensus represents the middle ground. Our model's $154-$322 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.